Shield Therapeutics revenue jumps on rising Accrufer prescriptions

(Alliance News) - Shield Therapeutics PLC on Wednesday said it is on track to turn free cash flow positive by the end of the year, as the pharmaceutical company reported a sharp rise in second quarter revenue.

Shares in the company jumped 16% to 4.11 pence each in London on Wednesday morning.

Shield Therapeutics, which has a focus on iron deficiency, said revenue in the second quarter of 2025 surged 86% on-year to USD12.8 million from USD6.9 million. It doubled on-quarter from USD6.4 million.

Total prescriptions of its Accrufer iron deficiency drug surged to 47,000 from 36,800 in the first quarter. The average net selling price rose on-quarter to USD231 from USD187.

"The company remains on track to achieve its prior guidance of turning cash flow positive by the end of 2025," Shield added.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Shield Thera